Search This Blog

Tuesday, February 11, 2025

"Get Violent And Fight": Tennessee Minister Calls For Attacks On 'Devil' Musk

 by Jonathan Turley,

Clearly, Dr. Steve Caudle of Greater Second Missionary Baptist Church in Chattanooga is not the “turn-the-other-cheek” type of minister. 

Caudle called upon his flock to choose violence in responding to the policy changes in progress in Washington with the new Administration. 

It is a further escalation of the rage rhetoric from Democratic politicians and pundits.

In a sermon live streamed to YouTube on Sunday, Caudle denounced Musk’s Department of Government Efficiency (DOGE) for threatening to “steal” Americans’ information and money, and said that a violent “conflict” will be coming:

In this nation, I’m worried that we are on the verge of bloodshed. This is an attempt to take us back to a day that we do not want to go, and we will not go. Therefore, there will be conflict. I pray that the peace of God will win out and overcome the madness that is attempting to take over this nation.”

“And I will say to you, beloved: no one likes violence, but sometimes violence is necessary. When Elon Musk forces his way into the United States Treasury, and threatens to steal your personal information and your social security check, there is a possibility of violence. 

Sometimes the devil will act so ugly, that there is no other choice but to get violent and fight!

Invoking Matthew 11:12, he added:

“… Why not talk this way? Because Jesus did… Jesus said in this key verse… ‘The kingdom of Heaven suffers — what — violence. And the who — the violent — take it by force. The kingdom of God is a warzone, it is a battlefield. You did know this, right?”

There is a normalization of such violent rhetoric with mainstream figures. 

The result can be a sense of license for some willing to turn to violent forms of expression, particularly when given the patina of moral justification.

As I have previously written, rage rhetoric has long been a part of our political process. However, when religious figures rationalize violent action, we cross a dangerous Rubicon in the use of such rhetoric.

*  *  *

Jonathan Turley is the Shapiro professor of public interest law at George Washington University and the author of “The Indispensable Right: Free Speech in an Age of Rage.”

https://www.zerohedge.com/political/get-violent-and-fight-tennessee-minister-calls-attacks-devil-musk

Canada, EU Condemn Trump Steel And Aluminum Tariffs, Vow To Retaliate

 The European Union and Canada vowed to respond after President Trump decided to impose tariffs on all steel and aluminum imports, escalating fears of a trade war. Trump signed proclamations late on Monday raising the U.S. tariff rate on aluminum to 25% from his previous 10% rate and eliminating country exceptions and quota deals as well as hundreds of thousands of product-specific tariff exclusions for both metals.

The measures, which will take effect on March 12, will apply to millions of tons of steel and aluminum imports from Canada, Brazil, Mexico, South Korea and other countries - but mostly Canada - that had been entering the U.S. duty free under the carve-outs. 

As noted last night, Canada is by far the most impacted from hike on steel and aluminum tariffs, as the country is by far the largest exporter of the two commodities to the US.

Steel imports accounted for about 23% of American steel consumption in 2023, according to American Iron and Steel Institute data, with Canada, Brazil and Mexico the largest suppliers. Canada, whose abundant hydropower resources aid its metal production, accounted for nearly 80% of U.S. primary aluminum imports in 2024.

Speaking during a visit to Paris on Tuesday, Canada's Prime Minister Justin Trudeau called the tariffs "unacceptable" adding that, if necessary, Canada's response would be firm and clear: Canadians will stand up strongly and firmly if we need to," he said.

Meanwhile Canada's version of Victoria Nuland and Samantha Power combined, Chrystia Freeland, who is also vying for Trudeau's job, warned Trump in no uncertain terms that this aggression toward Canada will not stand.

European Commission President Ursula von der Leyen also condemned the decision, saying the 27-nation bloc would take "firm and proportionate countermeasures".

“I deeply regret the US decision to impose tariffs on European steel and aluminum exports,” European Commission President Ursula von der Leyen said in a Tuesday statement. “Unjustified tariffs on the EU will not go unanswered — they will trigger firm and proportionate countermeasures.”

Von der Leyen added that tariffs were taxes that were bad for business and worse for consumers. EU steel exports to the U.S. have averaged about 3 billion euros ($3.1 billion) a year over the past decade.

The EU has prepared multiple lists of American goods to hit with retaliatory tariffs if Trump moves forward with levies, modeling various possibilities depending on what the initial US salvo looks like, Bloomberg reported earlier. The bloc could move quickly by re-applying duties it first imposed on the US during Trump’s first term.

One option for the EU would be to reactivate the tariffs it imposed in 2018 that were suspended under a truce agreed between Von der Leyen and then-U.S. president Joe Biden. The EU tariffs on U.S. products such as bourbon, motorcycles and orange juice are currently suspended until the end of March.

In figures likely to further irk Trump, Germany's trade surplus with the U.S. reached a record level last year of 70 billion euros ($72.3 billion), according to data from the German statistics office.


The American Chamber of Commerce to the EU (AmCham EU), representing U.S. companies active in Europe, also criticised the move as harmful to jobs, prosperity and security on both sides of the Atlantic.

"The damage will extend beyond just the steel and aluminium sectors, impacting all businesses that rely on these materials throughout the supply chain," it added in a statement.

The tariffs follow through on Trump’s complaint that the EU treats the US “very unfairly,” and he often cites the bloc’s trade surplus with the US as a reason for punitive measures.

The move will simplify tariffs on the metals "so that everyone can understand exactly what it means," Trump told reporters. "It's 25% without exceptions or exemptions. That's all countries, no matter where it comes from, all countries."

Trump also said he would follow with announcements about reciprocal tariffs on all countries that impose duties on U.S. goods over the next two days, and said he was also looking at tariffs on cars, semiconductors and pharmaceuticals.

Trump also will impose a new North American standard requiring steel imports to be "melted and poured" and aluminum to be "smelted and cast" within the region to curb U.S. imports of minimally processed Chinese and Russian metals that circumvent other tariffs. While China exports only tiny volumes of steel to the U.S., it is responsible for much of the world's excess steel capacity, according to the U.S. It says subsidised production in China forces other countries to export more and leads to transshipment of Chinese steel through other countries into the U.S. to avoid tariffs and other trade restrictions.

In the end, however, Trump is once again right to seek reciprocal trade terms, because as shown in the chart below, the US has the lowest trade-weighted tariff rate across virtually the entire developed world.

Shares in major listed steelmakers in China slid on Tuesday while shares of U.S. steel and aluminum manufacturers in the U.S. were set for gains.

https://www.zerohedge.com/economics/eu-and-canada-condemn-trump-still-aluminum-tariffs-vow-retaliate

'Massive Increase In "Despair And Burn Out" Among Democrats Seen"

 by Steve Watson via Modernity.news,

Leftist outlet Axios has published an article claiming that mental health experts are seeing a huge increase in patients who are Democrat voters complaining of “despair and burn out” in the wake of President Trump winning the election and taking office for the second time.

The piece claims that the worn out whiners are whinging about not being able to keep up with the pace of Trump’s “rapid fire policies.”

The article notes “Mental health professionals say even people who don’t see themselves as directly affected by administration actions are feeling frazzled by the dizzying pace and Trump’s enduring ability to command attention.”

“They may feel it through the venting of a spouse, the distress of a neighbor with a trans child or an anxious friend who works for a government contractor,” it hilariously adds.

The piece further states that Andrea Bonior, a Georgetown University psychology professor “said she’s seen an uptick in patients, particularly Democrats, expressing a sense of burnout, guilt and despair at losing an old way of life.”

It adds that “Bonior pointed to federal workers who aren’t sure if they’ll be let go as well as others concerned about their immigration status or worried about loved ones whose refugee flights were canceled.”

“It feels, no matter which way you go, you’re like, ‘Oh, my God, I’m being ruled by a very different system that I thought I was living in,'” New York-based neuropsychologist Sanam Hafeez told Axios.

Yes.

Won’t someone think of the bureaucratic federal workers and the illegal immigrants who now face “uncertainty” because borders and limits on government spending have been restored.

The world’s smallest violin is playing for them.

Perhaps these despairing Democrats need to hold some more group crying sessions and go ‘forest bathing.’

Pollster Mark Halperin previously predicted that America will experience the biggest mental health crisis in its history during a second Trump term.

Halperin urged that Trump has been so demonised for years that for tens of millions of Americans, Trump now becoming President again is “so traumatic” that it will become “impossible for even the most mentally healthy person to truly process and incorporate in the daily life.”

“They think that their fellow citizens supporting Trump is a sign of fundamental evil at the heart of their fellow citizens and of the nation,” concluded Halperin.

We’re already seeing Democrats completely losing it, screeching about Elon Musk being a Neo-Nazi and one State Rep. even saying she has sterilised herself as a protest against Trump.

*  *  *

https://www.zerohedge.com/political/mental-health-experts-see-massive-increase-despair-and-burn-out-among-democrats

Judge Blocks Federal Government From Cutting Medical Research Funding

 by Zachary Stieber via The Epoch Times,

U.S. District Judge Angel Kelley entered a temporary restraining order on Feb. 10 preventing the federal government from cutting medical research funding in 22 states in response to a lawsuit filed in federal court in Massachusetts.

The order is in place until further word from the court, Kelley said.

Government lawyers were also ordered to, within 24 hours, and at biweekly intervals thereafter, confirm with the judge that they are regularly disbursing medical research funding in the states, which include Arizona, California, Connecticut, Massachusetts, New York, and Oregon.

California, New York, and Massachusetts receive the most funding from the National Institutes of Health (NIH).

The legal challenge targets the U.S. National Institutes of Health directive that imposes a lower cap on indirect research costs for institutions receiving government funding after a quarter of $35 billion in NIH research funds went to indirect costs in 2024.

The new cap was set in the Feb. 7 directive at 15 percent, which is largely in line with private funding limits, and down from what the NIH said was an average of 27 percent to 28 percent.

“The United States should have the best medical research in the world. It is accordingly vital to ensure that as many funds as possible go towards direct scientific research costs rather than administrative overhead,” according to an NIH memorandum from the agency’s Office of the Director.

Dr. Matthew Memoli is the acting NIH director while the Senate considers President Donald Trump’s nominee, Dr. Jay Bhattacharya.

In an emergency motion for a temporary restraining order, attorneys general representing the states alleged that institutions, if the change were allowed to go through, would lead to “catastrophic financial consequences, which could result in layoffs and furloughs, research program closures, financial defaults, and disruptions to clinical trials, potentially jeopardizing people’s lives and health.”

The states also said the change violates a law that prohibits the NIH from changing the cap on indirect research costs.

“Even were NIH to have the authority it claims, a demanding regulatory process would be required; but NIH took none of the steps mandated by that process. In addition, the agency did not consider the detrimental effect of its decision on ongoing research that NIH itself has determined is integral to public health,” the motion stated

“Nor did NIH address the considerable reliance interests that are impaired when thousands of existing grants, totaling billions of dollars, are changed unilaterally over a weekend.”

The government has not issued a response to the motion.

After granting the request for a restraining order, Kelley set a hearing on the matter for Feb. 21.

https://www.zerohedge.com/political/judge-blocks-federal-government-cutting-medical-research-funding

Third Harmonic Phase 1 Results, Corporate Strategic Update

 THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU)

Company initiating process to leverage balance sheet strength to maximize shareholder value

Cash and cash equivalents of approximately $285 million as of December 31, 2024 (unaudited)

Management to hold conference call/webcast today Tuesday, February 11, 2025, at 8:00 a.m. EST to discuss clinical results and corporate next steps

Corporate Strategic Outlook
In parallel with THB335 Phase 2 readiness activities, Third Harmonic Bio is initiating a process to identify opportunities to maximize shareholder value through a strategic transaction and/or business combination. The Company has engaged TD Cowen to advise on this process.

In conjunction with this announcement, the Company is halting all non-THB335 related research and discovery activities and undertaking a reduction in workforce of approximately 50%.

As of December 31, 2024, the Company had approximately $285 million in cash and cash equivalents (unaudited). After accounting for expenses related to THB335 Phase 2 readiness activities, continuing operations, and restructuring costs, the Company estimates it will have cash and cash equivalents in a range of approximately $262 million to $267 million on June 30, 2025.

Conference Call and Webcast
The conference call and webcast will take place today at 8:00 a.m. EST / 5:00 a.m. PST on February 11, 2025. Please click here to pre-register to participate in the conference call and obtain your dial in number and PIN.

A webcast of the live call will be available online under events and presentations within the investor relations section of the Third Harmonic Bio website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company’s website for approximately 90 days.

https://www.globenewswire.com/news-release/2025/02/11/3024041/0/en/Third-Harmonic-Bio-Announces-Phase-1-Clinical-Results-for-THB335-and-Provides-Corporate-Strategic-Update.html

Oramed in JV to Accelerate Development and Commercialization of Oral Insulin

 New Standalone Company, OraTech Pharmaceuticals Inc., to Focus on Oral Drug Delivery with Strategic Investment and Advanced Manufacturing Capabilities

  • Oramed shareholders to receive the right to a direct stake in OraTech, expected to go public on Nasdaq.
  • OraTech will have global marketing rights to Oramed's POD™ oral protein delivery technology.
  • HTIT to invest $60 million, Oramed to invest $15 million into OraTech.
  • HTIT to provide a supply agreement for oral insulin capsules.
  • New Phase 3 trial in the U.S. with a revised protocol expected to begin this quarter.
  • OraTech to advance registration of oral insulin in the U.S. and other countries.
  • OraTech to receive royalty payments from sales of oral insulin in China, where a Marketing Authorization Application has been submitted, and commercialization preparations are underway by HTIT.
Further details on Oramed's plans and initiatives will be provided in a shareholder letter in the coming weeks.

Novartis buys Blackstone's Anthos for up to $3.1 b

 Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a biopharma firm majority-owned by Blackstone's drug development unit, for up to $3.1 billion, to boost its cardiovascular business.

Anthos was founded by private equity firm Blackstone's Life Sciences business and by Novartis in 2019 to develop, manufacture, and commercialise abelacimab, a treatment to prevent strokes and the recurrence of blood clots.

The deal underlines the Swiss group's commitment to cardiovascular therapies, one of five medical areas that it is focusing on, as its best-selling heart failure drug Entresto loses patent protection this year.

The transaction, expected to close in the first half of this year, also concludes a high-profile development partnership between a drug major and a private equity firm, an emerging funding model that has been explored by the industry.

Novartis will pay $925 million upfront with additional payments of up to $2.15 billion, contingent on development achievements, the companies said in statements.

A Blackstone spokesperson said the deal was the largest sale to date of a majority-owned Blackstone Life Sciences company.

Reuters reported in December 2023 that Blackstone was exploring the sale of Anthos.

Abelacimab belongs to a novel class of drugs known as factor XI inhibitors, designed to replace established blood thinners Eliquis by Bristol Myers-Squibb and Pfizer as well as Xarelto by Johnson & Johnson and Bayer, which are billion dollar sellers.

Bristol-Myers Squibb, together with Johnson & Johnson, are working in late stages of clinical testing on drug candidate milvexian.

Merck & Co is also in the factor XI race with a mid-stage development candidate. Germany's Bayer in 2023 suffered a huge setback in its effort to advance its factor XI drug.

Nicholas Galakatos, chairman of Anthos' board of directors and global head of Blackstone Life Sciences, said the firm was proud to have launched and helped grow Anthos.

"We believe abelacimab has the potential to be a leader in the new class of Factor XI anticoagulants and are pleased to have Novartis as a committed partner to advance the development and commercialization of abelacimab as a potential treatment ... for the millions of patients at risk of strokes," he said.

Anthos is conducting several phase 3 clinical studies, with data from these trials expected in the second half of 2026, Blackstone said.

Novartis said it already holds a small minority equity interest in Anthos, but declined to detail the size of it.


https://finance.yahoo.com/news/novartis-agrees-acquire-anthos-3-064130513.html